Company
Delfi Diagnostics
A simple blood draw. A smarter first step in lung cancer screening.
Also known as DELFI Diagnostics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- select health systems and healthcare providers
- Legal name
- DELFI Diagnostics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
DELFI Diagnostics is a cancer detection company that uses AI and whole-genome sequencing to analyze DNA fragmentation patterns in blood, capturing signals that conventional liquid biopsy approaches often miss.
Funding snapshot
- Total raised
- $366MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $34.3M2025-12-01
Funding rounds
- Round, 2025
- $34.3M2025-12-01, SEC form D sold, 50 investors
- Round, 2022
- $225M2022-06-10, SEC form D sold, 44 investors
- Round, 2021
- $101M2021-01-12, SEC form D sold, 25 investors
- Round, 2019
- $5.5M2019-08-12, SEC form D sold, 7 investors
- Round, 2018
- $15.3K2018-06-18, SEC form D sold, 9 investors
Products
- Other
- DELFI-TF
- Other
- FirstLook Lung
Loading relationship preview